Monday, July 28, 2014
Inquirer Daily News

Daniel Hoffman

A Response and an observation to big pharma scandal

Thursday, September 19, 2013, 6:00 AM
An astute reader shared his view of last week’s posting that discussed the scandal involving pharma companies allegedly bribing Chinese physicians and administrators. He made the point that in most industries, paying marketing-sales people on the basis of sales volume will make them eventually... Read more

Some big Pharmas step in duck sauce

Wednesday, September 11, 2013, 6:00 AM
Over the past several weeks GlaxoSmithKline (GSK) has contended with a major scandal at its national affiliate in China. Chinese Justice officials obtained testimony from numerous GSK employees, including some managers, that the company regularly paid bribes to physicians, hospital administrators... Read more

A fast way to cut health care costs

Thursday, September 5, 2013, 6:00 AM
By this point it is widely understood that health care costs represent the largest single factor behind growing federal budget deficits. During 2009 and 2010 the Obama administration argued for passing the Affordable Care Act by claiming it would substantially slow this drain on federal spending.... Read more

Two updates on pharma news

Thursday, August 29, 2013, 9:19 AM
Earlier this month we discussed how a major device manufacturer, Medtronic, blazed a trail for pharma by purchasing Cardiocom, a company that provides disease management and monitoring data for heart patients. Medtronic is well aware of the challenges facing device makers and the company decided to... Read more

Pharma's Denial and Rationalization Working Overtime

Monday, August 12, 2013, 11:42 AM
Evidence emerges almost every day that pharma's managers recognize the existence of serious problems threatening their industry, while at the same time most of them refuse to acknowledge the causes of this situation. Last week, for example, a provider of online marketing research released the results... Read more

A lesson or two from GSK's Chinagate

Monday, July 29, 2013, 6:00 AM
GlaxoSmithKline's (GSK's) Chinagate scandal of the past few weeks provides some belated insight on the China fantasy that pharma has been peddling to investors for much of the last decade. The basic pretense that pharma could somehow offset its wave of patent expirations, its dearth of compelling... Read more

Problems developing effective Alzheimer's therapies

Friday, July 19, 2013, 6:05 AM
Last week Eli Lilly announced that later this year it would start another late-stage (Phase 3) study of its monoclonal antibody, solanezumab, to test whether it can slow the advance of Alzheimer's disease. A pair of solanezumab Phase 3 trials last year failed to show efficacy in patients with mild-to-moderate... Read more

Which side is Pharma on?

Wednesday, July 10, 2013, 6:05 AM
Even as some health care trends slowly work their way to the surface, the mass media remains five years behind reality and has yet to recognize them. Yet the reactions of the world's nations to these trends will determine the nature of global health care in 2020 and beyond. The positions pharma takes... Read more

Nice bonds for conservative investors

Thursday, June 27, 2013, 10:12 AM
A monthly review of Big Cap pharma stocks by Sanford Bernstein, a large fee-analyst company, offers some insights in what it says and what it doesn't say. As with other equity analysts, Bernstein draws a wide distinction between a company's/sector's fundamentals and its value as a stock. Based on... Read more

The reactionary myth that's letting finance managers ruin pharma companies

Wednesday, June 19, 2013, 6:00 AM
Pharma's finance managers have come in for some heavy hits in this space during the past two years. They deserve every swat and then some. CFOs and their henchmen have destroyed Big Pharmas foundation as research-driven, growth companies and have driven off some of its most experienced, capable people... Read more
About this blog

Check Up covers major health events in our region and offers everything from personal health advice to an expert look at health reform. Read about some of our bloggers here.

For Portions of this blog may also be found in the Inquirer's Sunday Health Section

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Also on
Stay Connected